Pharmacoeconomic properties of disease-modifying antirheumatic drugs

TL;DRAbstract

The discipline of pharmacoeconomics has gained in importance in recent decades as countries and healthcare payers face pressures to justify investments in healthcare innovations. This situation has largely resulted from a coincidence of a demographic shift towards an increasingly elderly population and the development of effective and much more expensive therapies based in biotechnological advances. Many of these therapies improve health and may increase productivity and possibly prevent costly complications. Consequently health expenditures, previously considered “expenses”, are now more frequently referred to as “investments” to maintain a healthy and productive workforce [1]. Demonstration of “value for money” has become an important milestone for therapies on their way to rapid, and reimbursed, adoption.

Chat with Paper

AI Agents for this Paper